Deep Track Capital ATAI Position
Active3-Fund ConvergenceDeep Track Capital initiated a new position in Atai Beckley N.V. (ATAI) in Q4 2025, holding $19.1M worth of shares across 4,677,289 shares.
ATAI is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Atai Beckley N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
Full company profile →Short Interest
5.7%
3.3 days to cover
Frequently Asked Questions
Does Deep Track Capital own ATAI?
Yes. As of Q4 2025, Deep Track Capital holds 4,677,289 shares of Atai Beckley N.V. (ATAI) valued at $19.1M. This data comes from their SEC 13F filing.
How many hedge funds own ATAI?
3 specialist biotech hedge funds currently hold ATAI, including RTW Investments, OrbiMed Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy ATAI?
Deep Track Capital's position in ATAI was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's ATAI position increasing or decreasing?
Deep Track Capital initiated a new position in ATAI in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ATAICompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →